Longer survival with momelotinib than with best available therapy in ruxolitinib-pretreated myelofibrosis: results of a matching-adjusted indirect comparison

In a poster presented at the 2024 annual ASH meeting, Prof Francesca Palandri, haematologist in the IRCCS Azienda Ospedaliero at the University of Bologna (Italy), shared the results of a matching-adjusted, indirect comparison of momelotinib and best available therapy (BAT) in ruxolitinib-pretreated myelofibrosis patients. According to this analysis, momelotinib was associated with a longer overall survival (OS) than BAT, both in the overall study population and in the subgroup of patients with anemia at baseline. Together with the results of the SIMPLIFY-2 and MOMENTUM trials, these findings provide further support for the use of momelotinib as standard of care for myelofibrosis patients who discontinue their first line treatment with ruxolitinib.

According to Dr Heestermans, serial cfDNA analyses could improve the existing risk stratification of MM and inform clinicians about the emergence of (epi)genetic alterations with prognostic or therapeutic relevance. As such, this technique can contribute to a further personalization of the care for patients with MM.